Showing 2271-2280 of 23150 results for "".
Shared Goals, Shared Gains: Align With Patient Preferences
https://reachmd.com/programs/cme/shared-goals-shared-gains-align-with-patient-preferences/54776/Explore treat-to-target strategies and FcRn inhibitor use to guide outcomes-driven management of generalized myasthenia gravis.Decoding Bloating: Clinical Assessment and Therapeutic Approaches
https://reachmd.com/programs/gi-insights/decoding-bloating-clinical-assessment-and-therapeutic-approaches/18075/Tune in to learn how a gastroenterologist addresses patients’ concerns about bloating.Emerging Evidence for Perioperative ICIs in Locally Advanced HNSCC
https://reachmd.com/programs/cme/emerging-evidence-for-perioperative-icis-in-locally-advanced-hnscc/36593/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Factors Influencing Biologic Therapy Switching in Psoriasis and Psoriatic Arthritis
https://reachmd.com/programs/frontlines-psoriasis/factors-influencing-biologic-therapy-switching-in-psoriasis-and-psoriatic-arthritis/32430/Explore key findings from a recent study analyzing the factors that drive biologic therapy switching in patients with psoriasis and psoriatic arthritis.Discussing Drug Diversion: An Exploration of Impact & Prevention Through Smart Data
https://reachmd.com/programs/clinicians-roundtable/discussing-drug-diversion-an-exploration-of-impact-prevention-through-smart-data/12560/Learn about the impact of drug diversion and how can smart data help.KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
https://reachmd.com/clinical-practice/oncology-hematology/keynote-717-randomized-phase-2-trial-of-adding-local-hypofractionated-radiotherapy-to-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-cancer/39778/In the phase 2 KEYNOTE-717 trial, adding local hypofractionated radiotherapy to pembrolizumab improved systemic response rates in recurrent or metastatic HNSCC.Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels
https://reachmd.com/programs/neurofrontiers/monitoring-multiple-sclerosis-the-role-of-serum-neurofilament-light-chain-levels/17889/Read about a recent study that explored serum neurofilament light chain as a biomarker for monitoring disease activity in multiple sclerosis.Evaluating the Safety of Ixekizumab in Psoriasis and Arthritis Patients
https://reachmd.com/programs/clinicians-roundtable/evaluating-the-safety-of-ixekizumab-in-psoriasis-and-arthritis-patients/32447/Learn about the risk of adverse events associated with ixekizumab in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis.Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
https://reachmd.com/programs/spotlight-attr-cm/vutrisiran-for-attr-cm-exploring-an-rnai-therapeutic/32419/Read about recent clinical trial findings on vutrisiran, an RNA interference therapeutic that has emerged as a potential option for patients with transthyretin amyloid cardiomyopathy.A Clinician’s Action Guide for Psoriasis Awareness Month
https://reachmd.com/programs/dermconsult/a-clinicians-action-guide-for-psoriasis-awareness-month/24125/Here’s how you can support patients, educate the public, and become a patient advocate during Psoriasis Awareness Month and beyond.